BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml
CA2660001
Phase 3 small_molecule active
Quick answer
BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml for Unresectable Stage III non-small cell lung cancer without progression is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Unresectable Stage III non-small cell lung cancer without progression
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active